Efficacy and safety of phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction / 中华男科学杂志
National Journal of Andrology
; (12): 631-634, 2005.
Article
en Zh
| WPRIM
| ID: wpr-339463
Biblioteca responsable:
WPRO
ABSTRACT
Phosphodiesterase 5 inhibitors are recommended as first-line treatment of erectile dysfunction in many guidelines, because of their convenience, higher efficacy, and less side-effects. Since its first launch in 1998, sildenafil has been currently the best investigated phosphodiesterase 5 inhibitor with respect to long-term trails and quantity. Clinical trials showed the efficacy of sildenafil compared with placebo in many of the groups of patients who have ED, including those with cardiovascular disease, diabetes mellitus, depression, radical prostatectomy and dialysis. Typically the adverse effects reported in patients from clinical trials of sildenafil have been mild to moderate, and commonly include flushing and dyspepsia and transient visual disturbances. This article summarized recent reports on efficacy and safety of phosphodiesters 5 inhibitors in the treatment of erectile dysfunction.
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Inhibidores de Fosfodiesterasa
/
Piperazinas
/
Purinas
/
Seguridad
/
Sulfonas
/
Usos Terapéuticos
/
Quimioterapia
/
Citrato de Sildenafil
/
Disfunción Eréctil
Tipo de estudio:
Clinical_trials
/
Guideline
Límite:
Humans
/
Male
Idioma:
Zh
Revista:
National Journal of Andrology
Año:
2005
Tipo del documento:
Article